Zoetis Inc. (NYSE:ZTS) Shares Sold by Flputnam Investment Management Co.

Flputnam Investment Management Co. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,075 shares of the company’s stock after selling 388 shares during the period. Flputnam Investment Management Co.’s holdings in Zoetis were worth $338,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Callahan Advisors LLC raised its holdings in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares in the last quarter. Pensionfund Sabic grew its position in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares during the last quarter. CIBC Asset Management Inc grew its position in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the last quarter. PFW Advisors LLC bought a new position in shares of Zoetis in the fourth quarter valued at $1,764,000. Finally, Alberta Investment Management Corp lifted its position in shares of Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after acquiring an additional 28,700 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of recent research reports. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler lifted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $215.90.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of ZTS opened at $170.47 on Tuesday. The business’s 50-day moving average is $166.42 and its 200-day moving average is $177.16. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $76.34 billion, a price-to-earnings ratio of 31.16, a P/E/G ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis’s payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.